1. Home
  2. JANX vs OMER Comparison

JANX vs OMER Comparison

Compare JANX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

N/A

Current Price

$10.13

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$13.29

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JANX
OMER
Founded
2017
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
JANX
OMER
Price
$10.13
$13.29
Analyst Decision
Buy
Buy
Analyst Count
18
3
Target Price
★ $33.14
$27.50
AVG Volume (30 Days)
946.4K
★ 1.2M
Earning Date
11-05-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 98.15
EPS
N/A
★ 0.13
Revenue
$10,000,000.00
★ $29,868,000.00
Revenue This Year
$174.21
N/A
Revenue Next Year
N/A
$66.13
P/E Ratio
★ N/A
$107.77
Revenue Growth
★ N/A
N/A
52 Week Low
$10.16
$6.70
52 Week High
$35.34
$21.24

Technical Indicators

Market Signals
Indicator
JANX
OMER
Relative Strength Index (RSI) 25.34 30.78
Support Level N/A $9.45
Resistance Level $14.47 $19.68
Average True Range (ATR) 1.16 0.92
MACD -0.48 -0.45
Stochastic Oscillator 0.33 8.90

Price Performance

Historical Comparison
JANX
OMER

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: